No signal was created. Models could not agree on a directional bias.
- •The core tension lies in whether the current price action represents a healthy consolidation within a structural bull trend driven by the Midjourney partnership or a terminal spike-exhaustion pattern following a 55% surge.
- •Models are divided on whether the cooling RSI and high volume indicate institutional accumulation at the $7.16 demand zone or a distribution phase preceding a mean reversion to the $4.41 Point of Control.
BFLY has experienced a sharp pullback from its recent highs near $8.94 to its current price of $7.37, retracing into a key support zone around $5.97– $7.16 on the 4-hour and 30-minute timeframes. This pullback follows a 55.9% surge driven by the Midjourney Medical partnership announcement, which remains a structural bullish catalyst for the company’s long-term revenue growth and adoption in the handheld ultrasound market. The stock is now trading above its SMA20 ( $5.81) and SMA50 ( $4.98) on the 4-hour chart, with RSI (63.72) cooling from overbought levels but still in bullish territory, suggesting the pullback is a healthy consolidation rather than a trend reversal. The volume profile shows elevated participation (5-day avg: 15.9M vs. 55-day baseline of 4.9M) , confirming institutional interest during the recent rally. The POC ( $4.41) and value area ( $3.89– $7.77) further support the idea that the $5.97– $7.16 zone is a high-probability demand area for a bounce. With the broad market regime characterized as "calm/bullish" and no immediate event risk, BFLY is poised to retest its recent highs near $8.82– $8.94 if support holds.
BFLY is reversing from a speculative Midjourney-driven blow-off (+55.9% on Jun 19) and is already down 17% today with 30-min momentum rolling over (bearish MACD zero-cross, RSI falling) . Price sits at the top of the 30-day value area (~ $7.77) and is stretched 27-48% above its 4h/1day moving averages with no fundamental support (-73.6% margin, D/E 10.33, dilution risk) , so the most likely path is continued mean-reversion of the spike toward the $6.40-6.50 region over the next 1-2 weeks as momentum-chasers exit.
- →A 4-hour candle close above $8.05 would confirm a reclaim of the upper value area and signal a continuation toward the $8.27 resistance level.
- →A 4-hour candle close below $5.97 would confirm a structural breakdown of the primary support zone and initiate a deeper downtrend toward the SMA20.
Individual Model Analysis
Bull/Bear CompetitionWinner: BEAR
BFLY's +55.9% Midjourney-driven spike is unwinding, with today's -17.25% reversal on extreme volume (z-score 8.22) signaling the speculative pop is failing while price sits stretched ~39-49% above its SMA 20/SMA 50 and against the upper Bollinger Band. With heavy air below toward the $5.97 support and value-area edge ( $3.89- $7.77, POC $4.41) , and weak fundamentals (-73.6% margins, D/E 10.33, dilution and FDA-clearance risk) , the path of least resistance is a continued mean-reversion lower over the coming 1-3 weeks. The 30-min bearish MACD zero-cross and falling lower-timeframe RSI confirm momentum is rolling over from the spike.
BFLY remains in a powerful uptrend (price +458% off the 52-week low, well above rising SMA 20/SMA 50 on both 4h and 1day) driven by the Midjourney Medical partnership catalyst that sparked a +55.9% surge. Today's -17.25% pullback is a giveback into the 30-min support shelf at $7.16 within an intact higher-timeframe trend, and the calm/bullish risk-on regime favoring small caps supports a bounce-and-continuation back toward the $8.27 4h resistance over the 1-3 week swing window.
No clear trading edge identified
Bull/Bear CompetitionWinner: BEAR
BFLY's 55.9% surge on the Midjourney Medical announcement has completely reversed, with the stock gapping down -17% from its $8.94 52-week high on massive volume (z-score 8.22) — a textbook failed breakout and distribution pattern. The 30-min MACD shows a fresh bearish zero-cross with negative and falling histogram, while the 4h RSI has collapsed -18.91 points in just 3 bars, confirming momentum exhaustion at the highs. With a P/E of -23.6, negative margins of -73.6%, D/E of 10.33, and the Seeking Alpha same-day analysis highlighting that the full-body scanner lacks FDA diagnostic clearance and Midjourney may design Butterfly out of their 3rd-gen scanner, the fundamental floor does not support the current market cap of $2.3B. The expected price path is a continued decline toward the 4h support at $5.97 over 1-3 weeks as the hype fully deflates.
BFLY is pulling back from a massive 55.9% surge triggered by the June 19 Midjourney Medical AI-ultrasound partnership, a genuine catalyst re-rating the stock's long-term addressable market. The higher timeframe trends (4h and daily) remain strongly bullish with price above SMAs and positive MACD, suggesting this is a healthy pullback within an uptrend rather than a reversal. Entering via limit near the $7.00 support zone (aligned with the 30-min support area and low-volume node) offers an attractive re-entry into the catalyst-driven momentum with a defined risk level at the $5.97 structural support.
Bull/Bear CompetitionBALANCED
Butterfly Network (BFLY) presents a high-risk, high-reward long opportunity driven by the recent Midjourney Medical partnership announcement, which catalyzed a 55.9% surge in the stock on massive volume. This partnership aims to integrate AI-driven ultrasound technology into clinical workflows, addressing a critical gap in accessible diagnostic tools and aligning with the broader digital health trend. The stock is currently retracing from its recent highs but remains above key support levels ( $5.97 on the 4h timeframe) , suggesting a potential pullback-to-support setup before resuming its upward momentum. The bullish regime, characterized by small-cap leadership and risk-on rotation, further supports this thesis, as does the elevated volume profile, indicating strong participation in the recent move.
BFLY is exhibiting a classic post-parabolic blowoff top after a 55.9% surge following the Midjourney Medical partnership announcement. The stock is now trading at $7.37, a staggering 458% above its 52-week low of $1.32, but 17.6% below its recent high of $8.94, signaling exhaustion. The 4h timeframe shows RSI at 63.72, falling after a peak, and a bearish MACD crossover on the 30-minute timeframe, indicating momentum is waning. The stock is now testing resistance at $8.27 (4h) and $8.82 (1day), with no immediate catalyst to justify further upside. The elevated volume state (z-score 8.22) suggests a climax move, and the lack of confirmation from the broader market (SPY +0.41%) further weakens the case for sustained upside.